Name: Latest research reports of Ajanta Pharma Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 1
Author: BOB Capital Markets Ltd.

Ajanta Pharma Ltd.

NSE: AJANTPHARM | BSE: 532331 | ISIN: INE031B01049 | Industry: Pharmaceuticals
| Expensive Performer

2576.8500 38.60 (1.52%)

NSE Mar 17, 2025 15:31 PM

26.06% Fall from 52W High

Volume: 93,024

Ajanta Pharma Ltd.

11 Dec 2024

2576.85

1.52%

Ajanta Pharma (SELL): No incremental triggers; valuation expensive

Sell: Ajanta Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

At our virtual conference AJP said it is not looking to venture into newer therapies in India in the next 1-2 years due to hefty valuations

Ajanta Pharma Ltd. is trading below all available SMAs